Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  News  >  Companies  >  All News

News : Companies

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance ProfessionalsCalendarSectors

Aelan Cell Technologies : Names King Jordan, Ph.D. to Its Scientific Advisory Board

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/13/2016 | 07:30pm CEST

SAN FRANCISCO, CA--(Marketwired - Jan 13, 2016) - Aelan Cell Technologies announced today the appointment of King Jordan, Ph.D. to its Scientific Advisory Board. Dr. Jordan is an Associate Professor in the School of Biology and Director of the Bioinformatics Graduate Program at the Georgia Institute of Technology.

Dr. Jordan combines academic expertise in biology and genetics with 20 years of experience in bioinformatics. His work entails the development and application of computational tools for the analysis of genome sequences, along with various 'omics' functional analyses, and he has published more than 100 papers in scientific journals such as Nature, Proceedings of the National Academy of Sciences, Nucleic Acids Research, and Bioinformatics. Additionally, Dr. Jordan has been awarded research grants from the National Institutes of Health (NIH), the National Science Foundation, the Centers for Disease Control and Prevention, the Georgia Research Alliance, and the Alfred P. Sloan Foundation.

"Dr. Jordan is a national expert in bioinformatics, and he will be an invaluable asset to our team at Aelan," said Victoria Lunyak, Ph.D., the President and CEO of Aelan. "We have worked with Dr. Jordan on research projects in the past, and we're looking forward to continuing to work with him as Aelan grows."

"Dr. Jordan brings an important scientific background in bioinformatics, as well as genomics," added Chester Aldridge, Chairman of Aelan's Board of Directors and CEO of U.S. Equity Holdings. "He also is an expert in big data analysis, something that will be critical for Aelan as the company continues to develop treatments and technologies." 

At the Georgia Institute of Technology, Dr. Jordan's laboratory conducts research in bioinformatics and genomics, focusing on the analysis of large data sets in hopes of furthering the scientific understanding of the molecular and genetic determinants of human health.

"I am very excited to join Aelan Cell Technologies as a member of its Scientific Advisory Board," Dr. Jordan said. "In past experiences working with Aelan, I have been very impressed, and I look forward to helping the company continue to expand its research and development capabilities over the coming months and years."

Dr. Jordan received a B.S. in Biology from the University of Colorado and earned his Ph.D. in Genetics from the University of Georgia, after which he trained at the National Center for Biotechnology Information at the NIH, widely considered the world's leading bioinformatics institute. Dr. Jordan has also worked to develop bioinformatics and genomics capacity outside the United States, particularly in Latin America. In 2012, he was named a Fulbright Fellow to Colombia, and he is the Co-Founder and Director of the PanAmerican Bioinformatics Institute. Additionally, Dr. Jordan serves as an external scientific advisor to BIOS -- the Colombian National Center of Bioinformatics.

In addition to his academic work, Dr. Jordan consults with industry partners to help provide custom solutions to their bioinformatics challenges through his company Genomic Informatics Consulting.

About Aelan Cell Technologies:
Aelan Cell Technologies is a San Francisco startup engaged in the research, discovery, development and commercialization of innovative biomedical technologies for the advancement of human health and longevity. With a growing intellectual property portfolio of disruptive technologies and medical tools, Aelan has assembled an experienced team -- bringing together scientific and business expertise -- to successfully lead its products through each phase of development.

Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=2949135


© Marketwired 2016
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news "Companies"
04:51aMYRIAD GENETICS 24 HOUR DEADLINE ALERT : Approximately 24 Hours Remain; ClaimsFiler Reminds Investors with Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Myriad Genetics, Inc. – MYGN
BU
04:50aOil falls on rising output, escalating China-U.S. trade spat
RE
04:46aINTERNATIONAL BUSINESS MACHINES : IBM pits computer against human debaters
AQ
04:46aCOCA COLA : MLK, Coca-Cola feature in Charleston teens' award-winning documentary
AQ
04:46aMOVING ON : 37 years after opening, Tony Jordan sells Georgetown Allstate agency
AQ
04:42aMYRIAD GENETICS, INC. : FINAL DEADLINE TOMORROW: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Myriad Genetics, Inc. and Reminds Investors with Losses in Excess of $100,000 to Contact the Firm
AC
04:37aZTE : Trump Readies More Tariffs for China--2d Update
DJ
04:36aMAN 1, MACHINE 1 : landmark debate between AI and humans ends in draw
AQ
04:35aTESLA : CEO Musk emails staff alleging employee 'sabotage'
RE
04:35aClinton-based water company end search for new merger partner
AQ
Latest news "Companies"
Advertisement